Literature DB >> 3657181

Surgical treatment of intestinal radiation injury.

J Mäkelä1, K Nevasaari, M I Kairaluoma.   

Abstract

A review of 43 consecutive patients requiring operation for serious intestinal radiation injury was undertaken to elucidate the efficacy of surgical treatment. The most common site of radiation injury was the rectum (19 cases), followed by the small bowel (13 cases), the colon (7 cases), and the combination of these (4 cases). The overall operative mortality was 14%; morbidity, 47%; and the postoperative symptom-free period, 18 +/- 30 months. Colostomy (N = 20) carried the lowest risk of mortality, 0%, as compared with resection (N = 17) and bypass procedure (N = 6), which were accompanied by the mortalities of 24% and 33%, respectively. During the follow-up (3-13 years) 12 patients (28%) died of recurrent cancer and 9 patients (21%) of persistent radiation injury, which yielded an overall mortality of 65% after resection and 50% and 65% after bypass and colostomy procedures, respectively. Continuing radiation damage led to 15 late reoperations. Ten of these were performed after colostomy, four after resection, and one after bypass. We conclude that colostomy cannot be regarded as a preferred operative method, because it does not prevent the progression of radiation injury and because it is, for this reason, associated with a higher late-complication rate. A more radical surgery is recommended but with the limitation that the operative method must be adapted to the operative finding.

Entities:  

Mesh:

Year:  1987        PMID: 3657181     DOI: 10.1002/jso.2930360204

Source DB:  PubMed          Journal:  J Surg Oncol        ISSN: 0022-4790            Impact factor:   3.454


  1 in total

1.  Colostomy is a simple and effective procedure for severe chronic radiation proctitis.

Authors:  Zi-Xu Yuan; Teng-Hui Ma; Huai-Ming Wang; Qing-Hua Zhong; Xi-Hu Yu; Qi-Yuan Qin; Jian-Ping Wang; Lei Wang
Journal:  World J Gastroenterol       Date:  2016-06-28       Impact factor: 5.742

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.